Nyxoah Reports Third Quarter 2026 Financial and Operating Results

Nyxoah reported a third-quarter 2026 operating loss of €21.9 million, down from €24.4 million a year earlier, citing higher gross profit and lower R&D expenses as it focuses on commercial execution. It held €77.1 million in cash, cash equivalents and financial assets as of September 30, and reaffirmed its 2026 outlook for global net revenue of €33 million to €35 million and gross margin of 60% to 62%. U.S. revenue grew 29% sequentially. The company said ACCCESS study results and a pending PMA supplement submission could support expanding Genio’s use to patients with complete concentric collapse.